- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05614739
En studie av LOXO-435 hos pasienter med kreft med en endring i et gen kalt FGFR3 (FORAGER-1)
En åpen, multisenterstudie av LOXO-435 (LY3866288) i avanserte solide tumorkrefter med FGFR3-endringer
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Study participation could last up to approximately 6 years, depending on which part of the study you join.
Studieoversikt
Status
Detaljert beskrivelse
This is an open-label, multi-center, phase 1 study in participants with FGFR3-altered advanced solid tumor malignancy including metastatic urothelial cancer (UC), muscle-invasive bladder cancer (MIBC), and low grade intermediate risk non-muscle-invasive bladder cancer (LG IR NMIBC). The study will be conducted in 2 phases. Phase 1a will assess safety, tolerability, and pharmacokinetics of Vepugratinib to determine the optimal dose for further expansion. Phase 1b will include dose expansion cohorts to evaluate the efficacy and safety of Vepugratinib as monotherapy or in combinations with other medicines that treat cancer.
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Telefonnummer: 1-317-615-4559
- E-post: LillyTrials@Lilly.com
Studer Kontakt Backup
- Navn: Physicians interested in becoming principal investigators please contact
- E-post: clinical_inquiry_hub@lilly.com
Studiesteder
-
-
-
Darlinghurst, Australia, NSW 2010
- Rekruttering
- St Vincent's Hospital
-
Hunter Region, NSW, Australia, 2310
- Rekruttering
- Calvary Mater Newcastle
-
St Leonards, Australia, 2065
- Rekruttering
- GenesisCare North Shore
-
Sydney, Australia, 2109
- Rekruttering
- Macquarie University
-
-
-
-
-
Toronto, Canada, M5G 2M9
- Rekruttering
- Princess Margaret Hospital
-
Vancouver, Canada, V5Z 1J3
- Rekruttering
- British Columbia Cancer Agency
-
-
-
-
Arizona
-
Tucson, Arizona, Forente stater, 85719
- Rekruttering
- University of Arizona - Cancer Center
-
-
California
-
Duarte, California, Forente stater, 91010
- Rekruttering
- City of Hope
-
Los Angeles, California, Forente stater, 90095
- Rekruttering
- University of California, Los Angeles (UCLA) - Division of Hematology-Oncology
-
Orange, California, Forente stater, 92868
- Rekruttering
- University of California - Irvine
-
Sacramento, California, Forente stater, 95817
- Rekruttering
- University of California (UC) Davis Comprehensive Cancer Center
-
Stanford, California, Forente stater, 94305
- Rekruttering
- Stanford Medicine Cancer Center
-
-
Florida
-
Orlando, Florida, Forente stater, 32804
- Rekruttering
- Advent Health
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Emory University Hospital
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637
- Rekruttering
- The University of Chicago Medical Center (UCMC)
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Rekruttering
- Indiana University (IU) Melvin and Bren Simon Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater, 70809
- Rekruttering
- Mary Bird Perkins Cancer Center
-
New Orleans, Louisiana, Forente stater, 70121
- Rekruttering
- Ochsner Clinic Foundation
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21231-2410
- Rekruttering
- Johns Hopkins Kimmel Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Rekruttering
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48201
- Rekruttering
- Barbara Ann Karmanos Cancer Institute
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63108
- Rekruttering
- Washington University in St. Louis
-
-
New York
-
New York, New York, Forente stater, 10021
- Rekruttering
- Weill Cornell Medicine
-
New York, New York, Forente stater, 10029
- Rekruttering
- Icahn School of Medicine at Mount Sinai
-
New York, New York, Forente stater, 10032
- Rekruttering
- Columbia University
-
New York, New York, Forente stater, 10065
- Rekruttering
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
-
New York, New York, Forente stater, 10016
- Rekruttering
- New York University (NYU)
-
Rochester, New York, Forente stater, 14642
- Rekruttering
- University of Rochester - Wilmot Cancer Institute
-
The Bronx, New York, Forente stater, 10467
- Rekruttering
- Montefiore Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- Rekruttering
- University of North Carolina (UNC) - Chapel Hill
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45267
- Rekruttering
- University of Cincinnati Medical Center (UCMC)
-
Columbus, Ohio, Forente stater, 43210
- Rekruttering
- The Ohio State University (OSU)
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- Rekruttering
- University of Oklahoma - Health Sciences Center
-
-
Pennsylvania
-
Lancaster, Pennsylvania, Forente stater, 17601
- Rekruttering
- Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- University of Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Rekruttering
- Thomas Jefferson University
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- Rekruttering
- University of Pittsburgh Medical Center
-
Pittsburgh, Pennsylvania, Forente stater, 15212
- Rekruttering
- Allegheny General Hospital
-
-
South Carolina
-
Myrtle Beach, South Carolina, Forente stater, 29572
- Rekruttering
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Tennessee Oncology
-
Nashville, Tennessee, Forente stater, 37212
- Rekruttering
- Vanderbilt University Medical Center
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Sarah Cannon and HCA Research Institute
-
-
Texas
-
Dallas, Texas, Forente stater, 75244
- Rekruttering
- University of Texas Southwestern
-
Dallas, Texas, Forente stater, 75251
- Rekruttering
- Texas Oncology, P.A
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84132
- Rekruttering
- University of Utah
-
-
Vermont
-
Burlington, Vermont, Forente stater, 05401
- Rekruttering
- University of Vermont Medical Center
-
-
-
-
-
Bordeaux, Frankrike, 33076
- Rekruttering
- Institut Bergonie
-
Lyon, Frankrike, 69373
- Rekruttering
- Centre Leon Berard
-
Villejuif, Frankrike, 94805
- Rekruttering
- Institut Gustave Roussy
-
-
-
-
-
Petah Tikva, Israel, 49100
- Rekruttering
- Rabin Medical Center, Beilinson Hospital
-
Tel HaShomer, Israel, 5265601
- Rekruttering
- Sheba Medical Center
-
-
-
-
-
Milan, Italia, 20132
- Rekruttering
- IRCCS Ospedale San Raffaele
-
Roma, Italia, 00168
- Rekruttering
- UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
-
-
-
-
-
Chiba, Japan, 277-8577
- Rekruttering
- National Cancer Center Hospital East
-
Nagoya, Japan, 464-8681
- Rekruttering
- Aichi Cancer Center Hospital
-
Tokyo, Japan, 104-0045
- Rekruttering
- National Cancer Center Hospital
-
Tokyo, Japan, 135-8550
- Rekruttering
- Cancer Institute Hospital of JFCR
-
-
-
-
-
Beijing, Kina, 100730
- Rekruttering
- Beijing Hospital
-
Beijing, Kina, 100142
- Rekruttering
- Beijing Cancer hospital
-
Guangdong, Kina, 510060
- Rekruttering
- Sun Yat-Sen University- Cancer Center
-
Hangzhou, Kina, 310002
- Rekruttering
- Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
-
Hangzhou, Kina, 310003
- Rekruttering
- Zhejiang Provincial People's Hospital
-
Shanghai, Kina, 200000
- Rekruttering
- Renji Hospital, Shanghai Jiaotong University School of Medicine
-
Tianjin, Kina, 300060
- Rekruttering
- Tianjin Medical University Cancer Institute & Hospital
-
Xi'an, Kina, 710061
- Rekruttering
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
-
-
-
GE Rotterdam, Nederland, 3015
- Rekruttering
- Erasmus MC
-
-
-
-
-
Bergen, Norge, 5021
- Rekruttering
- Haukeland University Hospital
-
Oslo, Norge, 0450
- Rekruttering
- Oslo University Hospital
-
-
-
-
-
Barcelona, Spania, 08908
- Rekruttering
- Institut Catala d'Oncologia - L'Hospitalet
-
Madrid, Spania, 28041
- Rekruttering
- Hospital Universitario 12 de Octubre
-
Madrid, Spania, 28050
- Rekruttering
- South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC
-
Madrid, Spania, 28033
- Rekruttering
- Fundacion MD Anderson International Espana
-
Santander, Spania, 39008
- Rekruttering
- Hospital Universitario Marques De Valdecilla
-
-
-
-
-
Manchester, Storbritannia, M20 4BX
- Rekruttering
- The Christie NHS Foundation Trust
-
Sheffield, Storbritannia, S10 2SB
- Rekruttering
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
-
-
-
Seoul, Sør -Korea, 05505
- Rekruttering
- Asan Medical Center
-
Seoul, Sør -Korea, 03080
- Rekruttering
- Seoul National University Hospital
-
Seoul, Sør -Korea, 03722
- Rekruttering
- Severance Hospital, Yonsei University Health System
-
Seoul, Sør -Korea, 06351
- Rekruttering
- Samsung Medical Center
-
-
-
-
-
Bonn, Tyskland, 53127
- Har ikke rekruttert ennå
- Universitaetsklinikum Bonn
-
München, Tyskland, 81675
- Rekruttering
- Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
-
Tübingen, Tyskland, 72016
- Rekruttering
- Universitaetsklinikum Tuebingen
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Cohort A1, C1, D1, and D2: Locally advanced or metastatic solid tumor malignancy with a qualifying FGFR3 alteration.
-
Cohort A2, B2, B5 and B7: Urothelial cancer (UC) that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration.
-
Cohorts B1 and B4: Urothelial cancer that is locally advanced or metastatic and have received prior erdafitinib.
-
Cohort B6: Muscle Invasive Bladder Cancer with a qualifying FGFR3 alteration.
-
Cohort B7: Urothelial cancer that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration and expression of human epidermal growth factor receptor 2 (HER2).
-
Cohort B8: Low Grade Intermediate Risk Non-Muscle Invasive Bladder cancer and a qualifying FGFR3 genetic alteration.
-
Measurability of disease:
- Cohort A1, D1, and D2: Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST v1.1).
- Cohorts A2, B1, B2, B4, B5, B7, and C1: Measurable disease required as defined by RECIST v1.1.
- Cohort B8: Baseline disease which includes at least 1 lesion.
-
Have an Eastern Cooperative Oncology Group (ECOG) performance status of:
- 0 or 1 for Cohorts A1, A2, B5, B6, B7, and B8.
- Less than or equal to 2 for Cohorts B1, B2, B4, C1, DI and D2.
-
Cohort B6: Must be eligible for radical cystectomy plus pelvic lymph node dissection and agree to undergo curative intent standard radical cystectomy plus pelvic lymph node dissection.
Exclusion Criteria:
-
Participants with primary central nervous system (CNS) malignancy.
-
Untreated or uncontrolled CNS metastases.
-
Current evidence of corneal keratopathy or retinal disorder. Individuals with asymptomatic ophthalmic conditions may be eligible.
-
Any serious unresolved toxicities from prior therapy.
-
Significant cardiovascular disease.
-
Prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF).
-
Active uncontrolled systemic infection or other clinically significant medical conditions.
-
Participants who are pregnant, lactating, or plan to breastfeed during the study or within 6 months of the last dose of study treatment. Participants who have stopped breastfeeding may be enrolled.
-
Cohort D1 only:
- Have had renal transplantation.
- Have a known history of nephrotic syndrome.
- Have uncontrolled fluid overload, including clinically significant ascites, pleural effusion, or peripheral edema.
- Have uncontrolled hypertension.
- Are on hemodialysis or similar.
-
Cohort D2 only:
- Have a history of:
- Ventricular tachycardia or ventricular fibrillation.
- Hypertrophic obstructive cardiomyopathy unless managed concurrently with atrial fibrillation.
- Wolff-Parkinson-White syndrome.
- Second- or third-degree atrioventricular block unless a functioning pacemaker is in place.
- Heart rate less than (<) 50 bpm.
- Have any of these medical conditions:
- Severe respiratory insufficiency.
- Sleep apnea syndrome.
- Myasthenia gravis.
- Acute narrow-angle glaucoma.
- Active liver disease or clinically significant hepatic impairment.
- History of myopathy or rhabdomyolysis with any HMG-CoA reductase inhibitor.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Phase 1a: Cohort A1 Vepugratinib Monotherapy Dose Escalation
Vepugratinib administered orally |
Oral
Andre navn:
|
|
Eksperimentell: Phase 1a: Cohort A2 Vepugratinib Monotherapy Dose Optimization
Vepugratinib administered orally |
Oral
Andre navn:
|
|
Eksperimentell: Phase 1b: Cohort B1, B2, B4, C1, and D1 Vepugratinib Monotherapy Dose Expansion
Vepugratinib administered orally |
Oral
Andre navn:
|
|
Eksperimentell: Phase 1b: Cohort B5 Vepugratinib Plus Pembrolizumab Plus Enfortumab Vedotin
Vepugratinib administered orally in combination with pembrolizumab administered IV and enfortumab vedotin administered IV |
IV Oral
Andre navn:
IV |
|
Eksperimentell: Phase 1b: MIBC Cohort B6 Vepugratinib Plus Pembrolizumab Plus Enfortumab Vedotin
Vepugratinib administered orally in combination with pembrolizumab administered IV and enfortumab vedotin administered IV |
IV Oral
Andre navn:
IV |
|
Eksperimentell: Experimental: Phase 1b: Cohort B7 Vepugratinib Plus Trastuzumab Deruxtecan
Vepugratinib administered orally in combination with trastuzumab deruxtecan administered IV |
Oral
Andre navn:
IV |
|
Eksperimentell: Phase 1b: NMIBC Cohort B8 Vepugratinib Monotherapy Dose Expansion
Vepugratinib administered orally |
Oral
Andre navn:
|
|
Eksperimentell: Phase 1b: Cohort D2 (Drug to Drug Interaction)
Vepugratinib Plus Midazolam Plus Digoxin Plus Rosuvastatin (Lead-In Only) followed by Vepugratinib Monotherapy Vepugratinib administered orally Midazolam with digoxin with rosuvastatin administered orally once per cycle for 2 cycles. |
Oral
Andre navn:
Oral Oral Oral |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Overall Response Rate (ORR)
Tidsramme: Up to Approximately 30 Months or 2.5 Years
|
Up to Approximately 30 Months or 2.5 Years
|
|
Pharmacokinetics (PK) of Vepugratinib: Area Under the Concentration versus Time Curve (AUC)
Tidsramme: Up to 2 Months
|
Up to 2 Months
|
|
PK of Midazolam, Rosuvastatin, and Digoxin Administered Alone and in the Presence of Vepugratinib: Area Under the Concentration versus Time Curve (AUC[0-inf])
Tidsramme: Up to 2 Months
|
Up to 2 Months
|
|
Complete Response Rate (CRR) in Participants with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG IR NMIBC)
Tidsramme: Up to approximately 24 months or 5 years
|
Up to approximately 24 months or 5 years
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change from Baseline in Bladder-Related Symptoms, Measured by Functional Assessment of Cancer Therapy - Bladder (FACT-Bl) Subscale (BlCS)
Tidsramme: Cycle 1 Day 1, Cycle 2 Day 1, and Cycle 3 Day 1 (28 Day Cycles)
|
Cycle 1 Day 1, Cycle 2 Day 1, and Cycle 3 Day 1 (28 Day Cycles)
|
|
Change from Baseline in Physical Function, Measured by FACT- Physical Well-Being Scale (PWB) Subscale
Tidsramme: Up to Approximately 30 Months or 2.5 Years
|
Up to Approximately 30 Months or 2.5 Years
|
|
Event-Free Survival (EFS) in Participants with Muscle Invasive Bladder Cancer (MIBC)
Tidsramme: Up to approximately 30 months or 2.5 years
|
Up to approximately 30 months or 2.5 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Patologiske prosesser
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Mannlige urogenitale sykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Neoplasmer etter histologisk type
- Neoplasmer, kjertel og epitel
- Neoplastiske prosesser
- Ureteriske sykdommer
- Karsinom
- Urinblæresykdommer
- Patologiske tilstander, tegn og symptomer
- Ikke-muskelinvasive blære-neoplasmer
- Ureterale neoplasmer
- Neoplasma Metastase
- Neoplasmer i urinblæren
- Urologiske neoplasmer
- Svovelforbindelser
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Hydrokarboner
- Karbohydrater
- Polysykliske forbindelser
- Glykosider
- Amides
- Pyrimidiner
- Steroider
- Smeltede ringforbindelser
- Hydrokarboner, halogenert
- Benzazepiner
- Sulfonamider
- Sulfoner
- Benzodiazepiner
- Fluorbenzener
- Hydrokarboner, fluorert
- Digitalis glykosider
- Kardenolider
- Hjertesglykosider
- Kardanolider
- Rosuvastatin kalsium
- Midazolam
- Digoksin
- pembrolizumab
- Enfortumab Vedotin
- trastuzumab deruxtecan
Andre studie-ID-numre
- 18594
- LOXO-FG3-22001 (Annen identifikator: Eli Lilly and Company)
- J4G-OX-JZVA (Annen identifikator: Eli Lilly and Company)
- 2022-502755-59-00 (Annen identifikator: EU CTR #)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .